StockData
Abbott Laboratories logo

Abbott Laboratories (ABT) operating KPIs

ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)

Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%

Abbott Laboratories continuous Glucose Monitoring (CGM — FreeStyle Libre & Lingo) Worldwide Revenue ($M) ($M)

Abbott's flagship biowearable franchise ($7.6B in FY2025, >94% of Diabetes Care revenue). Missing standalone quarters in 10-Q/10-K are split via 6M − Q1, 9M − 6M, and FY − 9M.

QuarterlyAnnual
Latest, Q2 2026
2,100
Period ended Jun 30, 2026
Change on a year earlier
+10.5%
1,900 in Q2 2025
History
29 quarters
Since Q1 2019
Sources
28
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedContinuous Glucose Monitoring (CGM — FreeStyle Libre & Lingo) Worldwide Revenue ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20262,100+10.5%SEC Filing (0001628280-26-050134) ↗
Q1 2026Mar 31, 20262,000+17.6%SEC Filing (0001628280-26-028357) ↗
Q4 2025Dec 31, 20252,000+11.1%SEC Filing (0001628280-26-002982) ↗
Q3 2025Sep 30, 20252,000+17.6%SEC Filing (0001628280-25-045049) ↗
Q2 2025Jun 30, 20251,900+18.8%SEC Filing (0001628280-25-035135) ↗
Q1 2025Mar 31, 20251,700+13.3%SEC Filing (0001628280-26-028357) ↗
Q4 2024Dec 31, 20241,800+28.6%SEC Filing (0001628280-25-002092) ↗
Q3 2024Sep 30, 20241,700+21.4%SEC Filing (0001628280-25-047131) ↗
Q2 2024Jun 30, 20241,600+23.1%SEC Filing (0001628280-24-032182) ↗
Q1 2024Mar 31, 20241,500+25.0%SEC Filing (0001628280-25-021090) ↗
Q4 2023Dec 31, 20231,400+16.7%SEC Filing (0001628280-25-007110) ↗
Q3 2023Sep 30, 20231,400+40.0%SEC Filing (0001628280-23-034544) ↗
Q2 2023Jun 30, 20231,300+17.6%SEC Filing (0001628280-23-025156) ↗
Q1 2023Mar 31, 20231,200+20.6%SEC Filing (0001628280-23-015699) ↗
Q4 2022Dec 31, 20221,200+20.0%SEC Filing (0001628280-24-005348) ↗
Q3 2022Sep 30, 20221,000+3.3%SEC Filing (0001628280-22-027550) ↗

Breakdown

What makes up continuous glucose monitoring (cgm — freestyle libre & lingo) worldwide revenue ($m)

Cite this data

StockData. (2026). Abbott Laboratories Continuous Glucose Monitoring (CGM — FreeStyle Libre & Lingo) Worldwide Revenue ($M) ($M), quarterly Q1 2019–Q2 2026 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/cgm-rev-ww

See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.